Healthcare Executive Focused on Personalized Medicine, Illumina
Gautam Kollu leads worldwide market development efforts for Illumina’s Reproductive & Genetic Health business. His teams are responsible for identifying and nurturing new markets for the application of NGS in diagnostics such as non-invasive prenatal testing, pre-implantation genetic screening and diagnosis, and pre-conception and newborn screening. Gautam is accomplished in the launch and commercialization of innovative healthcare technologies, having held leadership and executive roles in driving several successful products including Herceptin, Avastin, Kadcyla, Cometriq, Panorama, verifi and VeriSeq. He currently chairs the Global Fertility Alliance and tweets from @gautamkollu. He received an MBA from The Wharton School and a B. Tech. in Chemical Engineering from IIT Bombay.
Diagnosing genetic diseases using Whole Genome Sequencing
Whole genome sequencing is emerging as a powerful tool for advancing neonatal and pediatric patient care. Advancements in interpretation and gains in diagnostic yield that have contributed to this recent trend will be surveyed.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Innovative new technologies continue to evolve and improve. Whether it is repurposing DNA to store digital data, improving the analysis of metabolites in biological specimen, or the advancements in analyzing and visualizing single cell data, these new emerging fields are driving precision medicine into the future.